Vesole, David H <br/><br/>
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.  [electronic resource] 

 -  British journal of haematology  Oct 2015 
 - 52-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.13517  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Lenalidomide<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Oligopeptides--administration & dosage<br/>Survival Rate<br/>Thalidomide--administration & dosage<br/>Vorinostat